熊去氧胆酸联合还原型谷胱甘肽治疗脂肪性肝病的临床研究

Clinical Study of Ursodeoxycholic Acid Combined with Reduced Glutathione for Fatty Liver Disease

目的:观察熊去氧胆酸联合还原型谷胱甘肽治疗脂肪肝的疗效及安全性。方法:79例脂肪肝患者随机分为2组,治疗组40例,熊去氧胆酸胶囊0.25g,tid,po;还原型谷胱甘肽片0.2g,tid,po。对照组39例,单用熊去氧胆酸胶囊0.25g,tid,po。2组疗程均为3个月。观察患者的临床症状、肝功能、血脂的变化及药品不良反应。结果:治疗组总有效率(92.50%)显著高于对照组(76.92%),差异有统计学意义(P<0.05)。治疗后肝功能各指标较治疗前明显下降,与治疗前比较差异有统计学意义(治疗组P<0.01,对照组P<0.05)、血脂各指标较治疗前显著下降(均P<0.01),但治疗后治疗组肝功能、血脂各指标较对照组明显下降(P<0.05)。在观察过程中未发现明显的药品不良反应。结论:熊去氧胆酸对脂肪肝具有较好疗效,与还原型谷胱甘肽联用可明显地提高对脂肪肝的疗效,且无明显不良反应,安全性高。

OBJECTIVE： To observe the clinical efficacy and safety of ursodeoxycholic acid combined with reduced glutathione for fatty liver disease. METHODS： 79 patients with fatty liver were randomly divided into 2 groups： 40 patients in therapy group were treated with oral dose of Ursodeoxycholic acid capsules 0.25 g and Reduced glutathione tablets 0.2 g three times a day for 3 months, and 39 in control group treated with oral dose of Ursodeoxycholic acid capsules in the same period. Clinical symptom, hepatic function, blood lipid and adverse drug reaction were observed. RESULTS： The total effective rate of therapy group （92.50%） was higher than that of control group （76.92%）, there was statistical significance （P0.05）. After treatment, hepatic function of 2 groups were decreased significantly, there was statistical significance （therapy group： P0.01; control group： P0.05）. The level of blood lipid of 2 groups were also decreased significantly （P0.01）. Compared with control group, liver function and blood lipids of therapy group reduced significantly（P0.05）. No obvious adverse drug reaction was found during treatment. CONCLUSION： Ursodeoxycholic acid is effective in the treatment of fatty liver disease. Ursodeoxycholic acid combined with reduced glutathione can improve clinical efficacy significantly with sound safety and without obvious adverse drug reaction.